Linezolida Kabi

Linezolid, the active ingredient in Linezolida Kabi, is a oxazolidinone presented as an intravenous formulation for intravenous use. It treats complicated skin and soft tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by Gram‑positive bacteria including MRSA and VRE.

GNH USA supplies Linezolida Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Linezolida Kabi is an oxazolidinone antibiotic indicated for serious infections caused by Gram‑positive bacteria.

- Complicated skin and soft tissue infections: effective against MRSA and other Gram‑positive pathogens, helping to resolve infection and prevent spread. - Community‑acquired and nosocomial pneumonia: eradicates susceptible bacteria in the lungs, improving respiratory function. - Infections caused by Gram‑positive bacteria such as VRE: provides a therapeutic option when other agents fail, targeting resistant strains.

Linezolida Kabi may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Headache: transient cranial discomfort. - Metallic taste: altered taste perception. - Vomiting: occasional emesis. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count requiring monitoring. - Anemia: reduced red blood cell levels, potentially leading to fatigue. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Optic neuropathy: visual disturbances that may be irreversible. - Serotonin syndrome: risk when combined with serotonergic agents. - Myelosuppression: bone‑marrow suppression affecting multiple blood cell lines.

Before initiating therapy with Linezolida Kabi, several safety considerations should be observed.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes regularly during treatment. - Concomitant serotonergic agents: avoid or closely monitor for serotonin syndrome. - Prolonged therapy (>2 weeks): perform periodic complete blood counts to detect myelosuppression. - Pregnancy and lactation: prescribe only if the potential benefit outweighs the risk to the fetus or infant. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Linezolida Kabi can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - MAO inhibitors: may cause hypertensive crisis. - Serotonergic antidepressants (SSRIs, SNRIs, TCAs, MAOIs): increased risk of serotonin syndrome. - Rifampicin: reduces linezolid plasma concentrations, potentially lowering efficacy. - Warfarin: may potentiate anticoagulant effect and raise INR.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened bleeding risk when combined with thrombocytopenia. - Carbamazepine: may decrease linezolid levels, requiring efficacy monitoring. - Digoxin: possible increase in serum digoxin concentrations. - Oral contraceptives: may reduce hormonal effectiveness, advise alternative contraception.